Business Description
![Jazz Pharmaceuticals PLC Jazz Pharmaceuticals PLC logo](https://static.gurufocus.com/logos/0C00000PW8.png?14)
Jazz Pharmaceuticals PLC
NAICS : 325412
SIC : 2834
ISIN : IE00B4Q5ZN47
Compare
Compare
Traded in other countries / regions
JAZZ.USAJ7Z.GermanyJAZZ.Mexico IPO Date
2007-06-01Description
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.34 | |||||
Equity-to-Asset | 0.33 | |||||
Debt-to-Equity | 1.54 | |||||
Debt-to-EBITDA | 4.77 | |||||
Interest Coverage | 2.18 | |||||
Piotroski F-Score | 8/9 | |||||
Altman Z-Score | 1.4 | |||||
Beneish M-Score | -2.68 | |||||
WACC vs ROIC |
Growth Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 8.4 | |||||
3-Year EBITDA Growth Rate | 13.8 | |||||
3-Year EPS without NRI Growth Rate | -15.5 | |||||
3-Year FCF Growth Rate | 16.5 | |||||
3-Year Book Growth Rate | -2.7 | |||||
Future 3-5Y EPS without NRI Growth Rate | 49.1 | |||||
Future 3-5Y Total Revenue Growth Rate | 5.74 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 58.04 | |||||
9-Day RSI | 57.84 | |||||
14-Day RSI | 57.08 | |||||
6-1 Month Momentum % | -15.97 | |||||
12-1 Month Momentum % | -21.01 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.37 | |||||
Quick Ratio | 2.02 | |||||
Cash Ratio | 1.27 | |||||
Days Inventory | 525.51 | |||||
Days Sales Outstanding | 62.53 | |||||
Days Payable | 86.08 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3.5 | |||||
Shareholder Yield % | 0.27 |
Profitability Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 89.39 | |||||
Operating Margin % | 15.05 | |||||
Net Margin % | 10.1 | |||||
FCF Margin % | 26 | |||||
ROE % | 10.84 | |||||
ROA % | 3.49 | |||||
ROIC % | 8.88 | |||||
ROC (Joel Greenblatt) % | 54.58 | |||||
ROCE % | 5.75 | |||||
Years of Profitability over Past 10-Year | 8 |
GF Value Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 19.64 | |||||
Forward PE Ratio | 5.83 | |||||
PE Ratio without NRI | 7.54 | |||||
Shiller PE Ratio | 23.23 | |||||
Price-to-Owner-Earnings | 19.38 | |||||
PS Ratio | 2.02 | |||||
PB Ratio | 1.88 | |||||
Price-to-Free-Cash-Flow | 7.66 | |||||
Price-to-Operating-Cash-Flow | 7.28 | |||||
EV-to-EBIT | 19.12 | |||||
EV-to-Forward-EBIT | 9.06 | |||||
EV-to-EBITDA | 8.92 | |||||
EV-to-Forward-EBITDA | 6.98 | |||||
EV-to-Revenue | 2.77 | |||||
EV-to-Forward-Revenue | 2.68 | |||||
EV-to-FCF | 10.66 | |||||
Price-to-Projected-FCF | 0.65 | |||||
Price-to-Median-PS-Value | 0.48 | |||||
Earnings Yield (Greenblatt) % | 5.23 | |||||
FCF Yield % | 14.41 | |||||
Forward Rate of Return (Yacktman) % | 10.34 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:JAZZ
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Jazz Pharmaceuticals PLC Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 3,909.883 | ||
EPS (TTM) ($) | 5.82 | ||
Beta | 0.22 | ||
Volatility % | 19.69 | ||
14-Day RSI | 57.08 | ||
14-Day ATR ($) | 2.721877 | ||
20-Day SMA ($) | 112.1415 | ||
12-1 Month Momentum % | -21.01 | ||
52-Week Range ($) | 99.06 - 146.7 | ||
Shares Outstanding (Mil) | 61.75 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 8 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Jazz Pharmaceuticals PLC Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Jazz Pharmaceuticals PLC Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Jazz Pharmaceuticals PLC Frequently Asked Questions
What is Jazz Pharmaceuticals PLC(JAZZ)'s stock price today?
The current price of JAZZ is $114.24. The 52 week high of JAZZ is $146.70 and 52 week low is $99.06.
When is next earnings date of Jazz Pharmaceuticals PLC(JAZZ)?
The next earnings date of Jazz Pharmaceuticals PLC(JAZZ) is 2024-11-08 Est..
Does Jazz Pharmaceuticals PLC(JAZZ) pay dividends? If so, how much?
Jazz Pharmaceuticals PLC(JAZZ) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |